Global Prostate Cancer Diagnostics Market Analysis and Forecast 2024-2030

Global Prostate Cancer Diagnostics Market Analysis and Forecast 2024-2030


Summary

The prostate is a walnut-sized gland located behind the base of a man’s penis, in front of the rectum, and below the bladder. Cancer begins when healthy cells in the prostate change and grow out of control, forming a tumor. A tumor can be cancerous or benign. A cancerous tumor is malignant, meaning it can grow and spread to other parts of the body. A benign tumor means the tumor can grow but will not spread.
Prostate Cancer Diagnostics refers to using PSA, rectal exam, biopsy and others to diagnostic whether patients with breast cancer.

According to APO Research, The global Prostate Cancer Diagnostics market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Prostate Cancer Diagnostics is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Asia-Pacific market for Prostate Cancer Diagnostics is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The China market for Prostate Cancer Diagnostics is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Europe market for Prostate Cancer Diagnostics is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The major global companies of Prostate Cancer Diagnostics include OPKO, Genomic Health, Abbott, Beckman Coulter, Siemens Healthcare, bioMeriux, Roche, MDx Health and DiaSorin, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
Report Includes

This report presents an overview of global market for Prostate Cancer Diagnostics, market size. Analyses of the global market trends, with historic market revenue data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.

This report researches the key producers of Prostate Cancer Diagnostics, also provides the revenue of main regions and countries. Of the upcoming market potential for Prostate Cancer Diagnostics, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Prostate Cancer Diagnostics revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Prostate Cancer Diagnostics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2019 to 2030. Evaluation and forecast the market size for Prostate Cancer Diagnostics revenue, projected growth trends, production technology, application and end-user industry.

Prostate Cancer Diagnostics segment by Company

OPKO
Genomic Health
Abbott
Beckman Coulter
Siemens Healthcare
bioMeriux
Roche
MDx Health
DiaSorin
Myriad Genetics
Ambry Genetics
Prostate Cancer Diagnostics segment by Type

Tumor Biomarker Tests
Imaging
Biopsy
Other
Prostate Cancer Diagnostics segment by Application

Age Below 55
Age 55-75
Age Above 75
Prostate Cancer Diagnostics segment by Region

North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Prostate Cancer Diagnostics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Prostate Cancer Diagnostics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Prostate Cancer Diagnostics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Prostate Cancer Diagnostics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Prostate Cancer Diagnostics company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Prostate Cancer Diagnostics revenue, gross margin, and recent development, etc.
Chapter 8: North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: Middle East, Africa, and Latin America type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.


1 Market Overview
1.1 Product Definition
1.2 Prostate Cancer Diagnostics Market by Type
1.2.1 Global Prostate Cancer Diagnostics Market Size by Type, 2019 VS 2023 VS 2030
1.2.2 Tumor Biomarker Tests
1.2.3 Imaging
1.2.4 Biopsy
1.2.5 Other
1.3 Prostate Cancer Diagnostics Market by Application
1.3.1 Global Prostate Cancer Diagnostics Market Size by Application, 2019 VS 2023 VS 2030
1.3.2 Age Below 55
1.3.3 Age 55-75
1.3.4 Age Above 75
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Prostate Cancer Diagnostics Market Dynamics
2.1 Prostate Cancer Diagnostics Industry Trends
2.2 Prostate Cancer Diagnostics Industry Drivers
2.3 Prostate Cancer Diagnostics Industry Opportunities and Challenges
2.4 Prostate Cancer Diagnostics Industry Restraints
3 Global Growth Perspective
3.1 Global Prostate Cancer Diagnostics Market Perspective (2019-2030)
3.2 Global Prostate Cancer Diagnostics Growth Trends by Region
3.2.1 Global Prostate Cancer Diagnostics Market Size by Region: 2019 VS 2023 VS 2030
3.2.2 Global Prostate Cancer Diagnostics Market Size by Region (2019-2024)
3.2.3 Global Prostate Cancer Diagnostics Market Size by Region (2025-2030)
4 Competitive Landscape by Players
4.1 Global Prostate Cancer Diagnostics Revenue by Players
4.1.1 Global Prostate Cancer Diagnostics Revenue by Players (2019-2024)
4.1.2 Global Prostate Cancer Diagnostics Revenue Market Share by Players (2019-2024)
4.1.3 Global Prostate Cancer Diagnostics Players Revenue Share Top 10 and Top 5 in 2023
4.2 Global Prostate Cancer Diagnostics Key Players Ranking, 2022 VS 2023 VS 2024
4.3 Global Prostate Cancer Diagnostics Key Players Headquarters & Area Served
4.4 Global Prostate Cancer Diagnostics Players, Product Type & Application
4.5 Global Prostate Cancer Diagnostics Players Commercialization Time
4.6 Market Competitive Analysis
4.6.1 Global Prostate Cancer Diagnostics Market CR5 and HHI
4.6.2 Global Top 5 and 10 Prostate Cancer Diagnostics Players Market Share by Revenue in 2023
4.6.3 2023 Prostate Cancer Diagnostics Tier 1, Tier 2, and Tier 3
5 Prostate Cancer Diagnostics Market Size by Type
5.1 Global Prostate Cancer Diagnostics Revenue by Type (2019 VS 2023 VS 2030)
5.2 Global Prostate Cancer Diagnostics Revenue by Type (2019-2030)
5.3 Global Prostate Cancer Diagnostics Revenue Market Share by Type (2019-2030)
6 Prostate Cancer Diagnostics Market Size by Application
6.1 Global Prostate Cancer Diagnostics Revenue by Application (2019 VS 2023 VS 2030)
6.2 Global Prostate Cancer Diagnostics Revenue by Application (2019-2030)
6.3 Global Prostate Cancer Diagnostics Revenue Market Share by Application (2019-2030)
7 Company Profiles
7.1 OPKO
7.1.1 OPKO Comapny Information
7.1.2 OPKO Business Overview
7.1.3 OPKO Prostate Cancer Diagnostics Revenue and Gross Margin (2019-2024)
7.1.4 OPKO Prostate Cancer Diagnostics Product Portfolio
7.1.5 OPKO Recent Developments
7.2 Genomic Health
7.2.1 Genomic Health Comapny Information
7.2.2 Genomic Health Business Overview
7.2.3 Genomic Health Prostate Cancer Diagnostics Revenue and Gross Margin (2019-2024)
7.2.4 Genomic Health Prostate Cancer Diagnostics Product Portfolio
7.2.5 Genomic Health Recent Developments
7.3 Abbott
7.3.1 Abbott Comapny Information
7.3.2 Abbott Business Overview
7.3.3 Abbott Prostate Cancer Diagnostics Revenue and Gross Margin (2019-2024)
7.3.4 Abbott Prostate Cancer Diagnostics Product Portfolio
7.3.5 Abbott Recent Developments
7.4 Beckman Coulter
7.4.1 Beckman Coulter Comapny Information
7.4.2 Beckman Coulter Business Overview
7.4.3 Beckman Coulter Prostate Cancer Diagnostics Revenue and Gross Margin (2019-2024)
7.4.4 Beckman Coulter Prostate Cancer Diagnostics Product Portfolio
7.4.5 Beckman Coulter Recent Developments
7.5 Siemens Healthcare
7.5.1 Siemens Healthcare Comapny Information
7.5.2 Siemens Healthcare Business Overview
7.5.3 Siemens Healthcare Prostate Cancer Diagnostics Revenue and Gross Margin (2019-2024)
7.5.4 Siemens Healthcare Prostate Cancer Diagnostics Product Portfolio
7.5.5 Siemens Healthcare Recent Developments
7.6 bioMeriux
7.6.1 bioMeriux Comapny Information
7.6.2 bioMeriux Business Overview
7.6.3 bioMeriux Prostate Cancer Diagnostics Revenue and Gross Margin (2019-2024)
7.6.4 bioMeriux Prostate Cancer Diagnostics Product Portfolio
7.6.5 bioMeriux Recent Developments
7.7 Roche
7.7.1 Roche Comapny Information
7.7.2 Roche Business Overview
7.7.3 Roche Prostate Cancer Diagnostics Revenue and Gross Margin (2019-2024)
7.7.4 Roche Prostate Cancer Diagnostics Product Portfolio
7.7.5 Roche Recent Developments
7.8 MDx Health
7.8.1 MDx Health Comapny Information
7.8.2 MDx Health Business Overview
7.8.3 MDx Health Prostate Cancer Diagnostics Revenue and Gross Margin (2019-2024)
7.8.4 MDx Health Prostate Cancer Diagnostics Product Portfolio
7.8.5 MDx Health Recent Developments
7.9 DiaSorin
7.9.1 DiaSorin Comapny Information
7.9.2 DiaSorin Business Overview
7.9.3 DiaSorin Prostate Cancer Diagnostics Revenue and Gross Margin (2019-2024)
7.9.4 DiaSorin Prostate Cancer Diagnostics Product Portfolio
7.9.5 DiaSorin Recent Developments
7.10 Myriad Genetics
7.10.1 Myriad Genetics Comapny Information
7.10.2 Myriad Genetics Business Overview
7.10.3 Myriad Genetics Prostate Cancer Diagnostics Revenue and Gross Margin (2019-2024)
7.10.4 Myriad Genetics Prostate Cancer Diagnostics Product Portfolio
7.10.5 Myriad Genetics Recent Developments
7.11 Ambry Genetics
7.11.1 Ambry Genetics Comapny Information
7.11.2 Ambry Genetics Business Overview
7.11.3 Ambry Genetics Prostate Cancer Diagnostics Revenue and Gross Margin (2019-2024)
7.11.4 Ambry Genetics Prostate Cancer Diagnostics Product Portfolio
7.11.5 Ambry Genetics Recent Developments
8 North America
8.1 North America Prostate Cancer Diagnostics Revenue (2019-2030)
8.2 North America Prostate Cancer Diagnostics Revenue by Type (2019-2030)
8.2.1 North America Prostate Cancer Diagnostics Revenue by Type (2019-2024)
8.2.2 North America Prostate Cancer Diagnostics Revenue by Type (2025-2030)
8.3 North America Prostate Cancer Diagnostics Revenue Share by Type (2019-2030)
8.4 North America Prostate Cancer Diagnostics Revenue by Application (2019-2030)
8.4.1 North America Prostate Cancer Diagnostics Revenue by Application (2019-2024)
8.4.2 North America Prostate Cancer Diagnostics Revenue by Application (2025-2030)
8.5 North America Prostate Cancer Diagnostics Revenue Share by Application (2019-2030)
8.6 North America Prostate Cancer Diagnostics Revenue by Country
8.6.1 North America Prostate Cancer Diagnostics Revenue by Country (2019 VS 2023 VS 2030)
8.6.2 North America Prostate Cancer Diagnostics Revenue by Country (2019-2024)
8.6.3 North America Prostate Cancer Diagnostics Revenue by Country (2025-2030)
8.6.4 U.S.
8.6.5 Canada
9 Europe
9.1 Europe Prostate Cancer Diagnostics Revenue (2019-2030)
9.2 Europe Prostate Cancer Diagnostics Revenue by Type (2019-2030)
9.2.1 Europe Prostate Cancer Diagnostics Revenue by Type (2019-2024)
9.2.2 Europe Prostate Cancer Diagnostics Revenue by Type (2025-2030)
9.3 Europe Prostate Cancer Diagnostics Revenue Share by Type (2019-2030)
9.4 Europe Prostate Cancer Diagnostics Revenue by Application (2019-2030)
9.4.1 Europe Prostate Cancer Diagnostics Revenue by Application (2019-2024)
9.4.2 Europe Prostate Cancer Diagnostics Revenue by Application (2025-2030)
9.5 Europe Prostate Cancer Diagnostics Revenue Share by Application (2019-2030)
9.6 Europe Prostate Cancer Diagnostics Revenue by Country
9.6.1 Europe Prostate Cancer Diagnostics Revenue by Country (2019 VS 2023 VS 2030)
9.6.2 Europe Prostate Cancer Diagnostics Revenue by Country (2019-2024)
9.6.3 Europe Prostate Cancer Diagnostics Revenue by Country (2025-2030)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Russia
10 China
10.1 China Prostate Cancer Diagnostics Revenue (2019-2030)
10.2 China Prostate Cancer Diagnostics Revenue by Type (2019-2030)
10.2.1 China Prostate Cancer Diagnostics Revenue by Type (2019-2024)
10.2.2 China Prostate Cancer Diagnostics Revenue by Type (2025-2030)
10.3 China Prostate Cancer Diagnostics Revenue Share by Type (2019-2030)
10.4 China Prostate Cancer Diagnostics Revenue by Application (2019-2030)
10.4.1 China Prostate Cancer Diagnostics Revenue by Application (2019-2024)
10.4.2 China Prostate Cancer Diagnostics Revenue by Application (2025-2030)
10.5 China Prostate Cancer Diagnostics Revenue Share by Application (2019-2030)
11 Asia (Excluding China)
11.1 Asia Prostate Cancer Diagnostics Revenue (2019-2030)
11.2 Asia Prostate Cancer Diagnostics Revenue by Type (2019-2030)
11.2.1 Asia Prostate Cancer Diagnostics Revenue by Type (2019-2024)
11.2.2 Asia Prostate Cancer Diagnostics Revenue by Type (2025-2030)
11.3 Asia Prostate Cancer Diagnostics Revenue Share by Type (2019-2030)
11.4 Asia Prostate Cancer Diagnostics Revenue by Application (2019-2030)
11.4.1 Asia Prostate Cancer Diagnostics Revenue by Application (2019-2024)
11.4.2 Asia Prostate Cancer Diagnostics Revenue by Application (2025-2030)
11.5 Asia Prostate Cancer Diagnostics Revenue Share by Application (2019-2030)
11.6 Asia Prostate Cancer Diagnostics Revenue by Country
11.6.1 Asia Prostate Cancer Diagnostics Revenue by Country (2019 VS 2023 VS 2030)
11.6.2 Asia Prostate Cancer Diagnostics Revenue by Country (2019-2024)
11.6.3 Asia Prostate Cancer Diagnostics Revenue by Country (2025-2030)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 China Taiwan
11.6.9 Southeast Asia
12 Middle East, Africa, Latin America
12.1 MEALA Prostate Cancer Diagnostics Revenue (2019-2030)
12.2 MEALA Prostate Cancer Diagnostics Revenue by Type (2019-2030)
12.2.1 MEALA Prostate Cancer Diagnostics Revenue by Type (2019-2024)
12.2.2 MEALA Prostate Cancer Diagnostics Revenue by Type (2025-2030)
12.3 MEALA Prostate Cancer Diagnostics Revenue Share by Type (2019-2030)
12.4 MEALA Prostate Cancer Diagnostics Revenue by Application (2019-2030)
12.4.1 MEALA Prostate Cancer Diagnostics Revenue by Application (2019-2024)
12.4.2 MEALA Prostate Cancer Diagnostics Revenue by Application (2025-2030)
12.5 MEALA Prostate Cancer Diagnostics Revenue Share by Application (2019-2030)
12.6 MEALA Prostate Cancer Diagnostics Revenue by Country
12.6.1 MEALA Prostate Cancer Diagnostics Revenue by Country (2019 VS 2023 VS 2030)
12.6.2 MEALA Prostate Cancer Diagnostics Revenue by Country (2019-2024)
12.6.3 MEALA Prostate Cancer Diagnostics Revenue by Country (2025-2030)
12.6.4 Mexico
12.6.5 Brazil
12.6.6 Israel
12.6.7 Argentina
12.6.8 Colombia
12.6.9 Turkey
12.6.10 Saudi Arabia
12.6.11 UAE
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings